# **START FORM**

### 09.2024 UPDATE



(For Office Use Only) Indicate your office	s preferred level of engageme	nt from Novartis Patient Sup	port for this patient:*
Subcutaneous use — includes: Coverage, Prior Authorization, and Appe Support from the initial benefits verification authorization and appeals	eals Support: Covera through prior Support Benefit	use — includes (select one): ge, Prior Authorization, and A from the initial benefits verificat s Verification Only: verification without prior autho	tion through prior authorization and appeals
1 Patient Information For patients younger than 18 years of age, please	se provide a parent or guardian's	bhone number.	*=REQUIRED FIELDS
First Name* Last N	lame*	Email	Mobile
Date of Birth (MM/DD/YYYY)*	or Clinical Use: Male Fen	Phone Number*	☐ Home ough non-marketing calls/texts <sup>†</sup> )
Address (No PO Box)*		OK to Leave Voicemail:	<u></u>
	710+		_
City State I give permission to disclose my personal he	ZIP* ealth information to the followir	Preferred Language: [ na (optional):	English Spanish
			Other:
Name			
Phone Number† (We'll keep you updated through n	on-marketing calls/texts†)	Relationship to Patient	
X     Patient or Authorized Representative Sig	gnature ed representative  ONGOING SUPPORT FROM CO You can get additional one-on-on checking the box below.  I agree to receive marketing of and texts made with an autoco	alls and texts from and on behalf of	more about COSENTYX.  SUPPORT  lers, tips, and other communications by  Novartis and its affiliates, including calls none number(s) I provide. I understand that
3 Insurance Information*	u		de contra con esta de conserva de la
<u>Please include copies (front and back) of the benefit insurance as applicable.</u>	the patient's medical and pharr	nacy insurance card(s). Includ	de primary, secondary, and pharmacy
Check all that apply: Primary See	condary Prescription/Pha	rmacy Patient Is Uninsur	red
4 Provider Information			
First Name* Last N	Name* F	Practice Name*	-
Address		Practice Phone Number	
City State	ZIP*	Office Contact Name	Office Contact Phone
Provider NPI Number*	(	Office Fax*	
Tax ID Number* PTAN (Required to run benefits for IV patients)	l Number (	Office Email	
Send Fax 1-844-666-1366 or 1		nroll Online ww.CoverMyMeds.com	Questions? Call 1-844-267-3689

9/24

## START FORM 09.2024 UPDATE

## \*=REQUIRED FIELDS

	Patient Name*	Date of Birth (MM/DD/YYYY)*	
WI		/ /	



5 Treating Site Info please complete the info Please indicate your pro Non-Prescribing MD's If alternate site of service	rmation below. <b>eferred alternate s</b> s Office	site, if any: Hospital Ou	tpatient Facili					eive COSENTYX® (s		b) IV formulation	n,
Site Name*					Expecte	2d CO3	SENTYX Trea	/ tment Date (MM/D	/ )D/YYYY)		
- One Marile							DENTITY TICA	unioni Date (iviivi) D			
Address*					Phone						
City	Stat	e	ZIP*		Fax*						
Site NPI Number*	Tax	ID Number*			Contact	t Name		Con	tact Phone		
6 Additional Inform Primary Diagnosis/ICD  ☐ L73.2 Hidradenitis Sup  ☐ Other ICD-10-CM Cool	<b>P-10-CM</b> Codes (che ppurativa $\square$ M08.	90 Juvenile Ar	thritis, unspec	cified $\square$	M45.0 Ankylos	sing Sp	ondylitis 🗆 N	M45.A Non-Radiog	raphic Axial	Spondyloarthri	tis
Excluding COSENTYX, coptions below: (optional)  Cimzia®	_ Humira®	re a contraindio □ Otezla® □ Tremfya®	cation or have  Remicade	e <sup>®</sup> [	iously taken an  Rinvoq®  Methotrexate	□Si	e following treatimponi® ulfasalazine	atments below? If y  NSAIDs (diclof	fenac, ibupro		
7 Prescription Info		•	_	тару _	IVIOLI OLI CALLO		unaodiazino	_ other, list arag	, riamo(o)		
Covered Until You're Covered Free Medication Prescription Ship first dose to: Patient Office, as allowable by law HCP Preferred Specialty Pharmacy (optional): The patient prescription has been sent to the specialty pharmacy noted here  Pharmacy Prescription and Covered Until You're Covered*:											
Adult				Dosin	g (Qty 28 Days	s)				Refills	
COSENTYX 150 mg  ☐ Sensoready® Pen (1x150 mg/mL)	☐ Prefilled Syring (1x150 mg/mL)			□Mai		ct 150		eously on Weeks 0 eously on Week 4, t		N/A □ 12 refills, or	refills
				□Loa	□ <b>Loading Dose:</b> Inject 300 mg subcutaneously on Weeks 0, 1, 2, 3			0, 1, 2, 3	N/A		
COSENTYX 300 mg ☐ UnoReady® Pen (1x300 mg/2 mL)					☐ Maintenance: Inject 300 mg subcutaneously on Week 4, then every 4 weeks thereafter				then	☐ 12 refills, or	refills
(MOOOTHIG/EITIE/	(EXIOCING/IIIE)	, (2/10)	(ZXIOO IIIg/IIIL)	☐ Maintenance Increase (HS only): Inject 300 mg subcutaneously every 2 weeks (For patients currently taking COSENTYX every 4 weeks as per label. Loading dose already completed.)					neously every	☐ 12 refills, or	refills
Pediatric				Dosin	g (Qty 28 Days	s)				Refills	
COSENTYX 75 mg	☐ Prefilled Syring	e			□ <b>Loading Dose:</b> Inject 75 mg subcutaneously on Weeks 0, 1, 2, 3					N/A	
(wt < 50 kg) (1x75 mg/mL)			☐ Maintenance: Inject 75 mg subcutaneously on Week 4, then every 4 weeks thereafter					☐ 12 refills, or	refills		
COSENTYX 150 mg (wt ≥50 kg)	Sensoready® F (1x150 mg/mL)		☐ Prefilled Syringe (1x150 mg/mL)	□ Loading Dose: Inject 150 mg subcutaneously on Weeks 0, 1, 2, 3					N/A		
(	(IXIOO IIIg/IIIL)	(IXIOC	,g, <u>-</u> /		☐ Maintenance: Inject 150 mg subcutaneously on Week 4, then every 4 weeks thereafter			hen	☐ 12 refills, or	refills	
Provider Attestation Prescriber must authorize I certify the above therape the previously identified plauthorize NPAF, Novartical electronically, by facsimil discussed COSENTYX for the limited purpose and/or email.	e these instructions y is medically neces patient and I provide is Pharmaceuticals ( e, or by mail to the al	sary and this ir d the patient w Corporation, ar ppropriate disp Support with r	iformation is a ith a description od its affiliates bensing pharm ny patient, wl	accurate t on of COS s, business nacies. I w <b>ho has au</b>	SENTYX® Conn partners, and a ill not attempt t thorized me u	nect Pa agents o seek <b>inder F</b>	tient Support. to forward as reimburseme IIPAA and sta	For the purposes of my agent, for these ont for free product telaw to disclose	of transmitting e limited purp provided to a e their inform	ng these prescri poses, the presc my office. <b>I have</b> <b>mation to Nova</b>	ptions, criptions <b>e</b> rtis
Provider Signature (Dispense as Written)* (Substitution Permissible) Provider Name (Print Name) Date (MM/DD/YYYY)*  ATTN: Please follow your state's prescribing guidelines for electronic prescriptions (if applicable)											
=	Send Fax				Enroll C	nline		P Que	estions? C	all	

www.CoverMyMeds.com

1-844-267-3689

9/24

1-844-666-1366 or 1-800-343-9117

# START FORM

#### 09.2024 UPDATE



#### **Patient Authorization**

I authorize my healthcare providers, pharmacies and health insurers, and their service providers ("Providers") to disclose information relating to my insurance benefits, medical condition, treatment, and prescription details ("Personal Information") to Novartis Pharmaceuticals Corporation, its affiliates and service providers ("Novartis") and the Novartis Patient Assistance Foundation. Inc., and its service providers ("NPAF") so they can provide the following support services (the "Services"):

- Help coordinate insurance coverage for access to and receipt of my medication.
- Communicate with me about possible financial assistance, including Novartis co-pay or NPAF programs, and, if I am enrolled, administer my participation in those programs.
- Communicate with me about my medication and treatment, including reminders, health and lifestyle tips, and product and other related information. Communications may be customized based on Personal Information obtained from my Providers.
- Conduct quality assurance and other internal business activities and ask for feedback related to the Services or my treatment.

In delivering the Services, Novartis and NPAF may share my Personal Information with each other, with my Providers, or with government agencies or other financial assistance programs that might help me pay for my medication. They may combine information collected from me with information collected from other sources and use that information to administer the Services. My pharmacies or other healthcare providers may receive payment from Novartis or NPAF for providing certain Services, such as medication or refill reminders, based on my enrollment or participation. Once I authorize disclosure of my Personal Information, it may no longer be protected by federal health privacy law and applicable state laws.

I understand I do not have to sign this Authorization to get my medication or insurance coverage, that I have a right to a copy, and can cancel this Authorization at any time by calling 1-844-267-3689 or by writing to:

Customer Interaction Center Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ 07936-1080

This Authorization will expire 5 years after I sign it, or earlier if required by state law, unless I cancel it sooner. If I cancel it, I may no longer qualify for Services from Novartis or NPAF, but it will not impact my Provider's treatment or my insurance benefits. I also understand that if a Provider is disclosing my Personal Information to Novartis or NPAF on an authorized, ongoing basis, my cancellation will be effective with respect to that Provider as soon as they receive notice of my cancellation. Cancellation will not affect prior uses or disclosures.

### **COSENTYX® Connect Co-Pay Offer Terms & Conditions**

Limitations apply. Valid only for those with private insurance. Program provides up to \$16,000 annually for the cost of COSENTYX and up to \$150 per infusion (up to \$1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state healthcare program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or healthcare savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the US and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

\*The Covered Until You're Covered Program is available for COSENTYX® (secukinumab) subcutaneous injection only. Eligible patients must have commercial insurance, a valid prescription for COSENTYX, and a denial of insurance coverage based on a prior authorization request. Program requires the submission of an appeal of the coverage denial within the first 90 days of enrollment in order to remain eligible. Program provides COSENTYX for free to eligible patients for up to two years, or until they receive insurance coverage approval, whichever occurs earlier. A valid prescription consistent with FDA-approved labeling is required. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Patients may be asked to reverify insurance coverage status during the course of the program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Limitations may apply. Enrolled patients awaiting coverage for COSENTYX after two years may be eligible for a limited Program extension. Novartis Pharmaceuticals Corporation reserves the right to rescind, revoke, or amend this Program without notice.

'Novartis Patient Support may call and text you at the numbers provided for non-marketing purposes (e.g., to help you access and start on COSENTYX). Calls may be autodialed or prerecorded. Message and data rates may apply. You may change your communication preferences at any time by calling 1-844-267-3689.

